US OptionsDetailed Quotes
CLLS250117P2500
- 0.00
- 0.000.00%
15min DelayTrading Dec 24 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover0.00%IV-59.03%PremiumJan 17, 2025Expiry Date0.93Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.70Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Cellectis Stock Discussion
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
Cellectis announced pre-clinical data presentation at SITC's 39th Annual Meeting, showcasing strategies to enhance CAR T-cell efficacy against solid tumors. The research focuses on overcoming challenges in the tumor microenvironment (TME) using TALEN®-mediated gene editing to generate allogeneic CAR T-cells. The company developed two key approaches: a FAP-depe...
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
Positive
Strong cash position of $264 million with runway extended into 2027
Significant revenue increase to $34.1 million, up from $7.2 million YoY
Net loss improved to $42.7 million from $59.3 million YoY
Secured $47 million in payments from AstraZeneca partnership
Negative
R&D expenses increased to $69.7 million from $62.7 million YoY
SG&A expenses rose to $14.2 million from $12....
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
Cellectis, a clinical-stage biotechnology company, will present pre-clinical data on TALE base editors (TALEB) and non-viral gene insertion at the European Society of Cell and Gene Therapy 31st annual congress in Roma, Italy, from October 22-25, 2024. Two posters will be showcased:
1. 'Controlling C-to-T editing with TALE base editors' by Alexandre Juillerat, Ph.D....
Cellectis Presents Pre-Clinical Evidence That TALEN-Edited MUC1 CAR T-Cells Reduce Triple-Negative Breast Cancer While Ensuring Safety
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published a scientific article in Science Advances suggesting that TALEN®-edited MUC1 CAR T-cells could be a potential treatment ...
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
Cellectis (NASDAQ: CLLS) has published an article in Molecular Therapy showcasing their innovative SMART DUAL CAR T-cell approach for treating solid tumors. Using TALEN® gene editing technology, Cellectis has developed allogeneic CAR T-cells that express:
1. A constitutive CAR targeting FAP+ cancer-associated fibroblasts (CAFs) in solid tumors
2. An...
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
Cellectis (NASDAQ: CLLS) announced that the FDA has granted Orphan Drug Designation (ODD) to CLLS52 (alemtuzumab), used in the lymphodepletion regimen for UCART22 in the BALLI-01 clinical trial for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). The addition of alemtuzumab to the fludarabine and cyclophosphamide regimen has shown sustained lymphodepletion and higher UCA...
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
Cellectis (NASDAQ: CLLS) announced that the FDA has granted Orphan Drug (ODD) and Rare Pediatric Disease Designation (RPDD) Status to its UCART22 product candidate for treating Acute Lymphoblastic Leukemia (ALL).
ALL represents 10% of leukemia cases in the US, progressing rapidly and often fatal if untreated.
The ...
Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
Cellectis announced a breakthrough in gene therapy for Sickle Cell Disease (SCD) using a non-viral approach published in Nature Communications. The therapy employs TALEN® technology for precise HBB gene correction in hematopoietic stem and progenitor cells (HSPCs). This method achieves over 50% expression of normal hemoglobin in treated cells, effectively correcting the s...
No comment yet